Cell therapy (TCR-T) · Kills target cells, directed at MAGE-A1 · developed by TScan Therapeutics
TSC-204-C0702 is an autologous T-lymphocyte preparation engineered to express a T-cell receptor specific for MAGE-A1 presented on HLA-C*07:02. The engineered cells recognize MAGE-A1 on tumor cells and mediate their elimination. It is being studied in head and neck, cervical, non-small cell lung, melanoma and ovarian cancers and other HPV-related cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05973487 | Phase 1 | Head and Neck Cancer | Active not recruiting | TCRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Anogenital CancersCervical CancerHead and Neck CancerHPV - Anogenital Human Papilloma Virus InfectionHPV Positive Oropharyngeal Squamous Cell CarcinomaHPV-Associated Vaginal AdenocarcinomaHPV-Related AdenocarcinomaHPV-Related Adenosquamous CarcinomaHPV-Related CarcinomaHPV-Related Cervical CarcinomaHPV-Related MalignancyHPV-Related Squamous Cell CarcinomaMelanomaNon-small Cell Carcinoma
Updated Nov 1, 2026. Something wrong or missing? Report it on the TCRX page.
See TCRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TCRX catalysts and pipeline →